Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0GB3P
|
|||
Drug Name |
Pyridazin-3(2H)-one derivative 1
|
|||
Synonyms |
PMID29334795-Compound-20
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
CEPHALON, INC. BIERLMAIER, Stephen HALTIWANGER, Ralph, Curtis JACOBS, Martin, JCEPHALON, INC. HUDKINS, Robert, L. JOSEF, Kurt, A. TAO, Ming BECKNELL, Nadine, C. HOSTETLER, Greg KNUTSON, Lars, J., S. ZULLI, Allison, L
|
|||
Structure |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Histamine H3 receptor (H3R) | Target Info | Inverse agonist | [1] |
Target's Patent Info | Histamine H3 receptor (H3R) | Target's Patent Info | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Reactome | Histamine receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | Monoamine Transport | |||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.